Evidence map›Paper›PMID 34815519›Full record

ArticleBone marrow transplantation2022

Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.

Nobuhiko Imahashi, Seitaro Terakura, Eisei Kondo, Koji Kato, Sung-Won Kim, Akihito Shinohara, Mizuki Watanabe, Takahiro Fukuda, Naoyuki Uchida, Hikaru Kobayashi and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 18 institutions in 1 country.

Nobuhiko ImahashiDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan. nimahashi@med.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0002-1398-2002
Seitaro TerakuraDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0002-1194-8046
Eisei KondoDepartment of Hematology, Kawasaki Medical School, Kurashiki, Japan.ORCID http://orcid.org/0000-0003-0995-9405
Koji KatoDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Sung-Won KimDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Akihito ShinoharaDepartment of Hematology, Tokyo Women's Medical University, Tokyo, Japan.ORCID http://orcid.org/0000-0002-5530-6133
Mizuki WatanabeDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-4030-4653
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Naoyuki UchidaDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5952-5926
Hikaru KobayashiDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Jun IshikawaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Keisuke KataokaDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Souichi ShiratoriDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.ORCID http://orcid.org/0000-0002-5528-7112
Takashi IkedaDivision of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan.ORCID http://orcid.org/0000-0003-3976-5230
Ken-Ichi MatsuokaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.ORCID http://orcid.org/0000-0001-7955-8266
Shuro YoshidaDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Tadakazu KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-8959-6271
Takafumi KimuraPreparation Department, Japanese Red Cross Kinki Block Blood Center, Osaka, Japan.
Makoto OnizukaDepartment of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.ORCID http://orcid.org/0000-0003-3864-0823
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.ORCID http://orcid.org/0000-0002-0393-4066
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.ORCID http://orcid.org/0000-0003-4404-2870
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-6704-3633
Kyoto University · JPHamanomachi Hospital · JPHiroshima University · JPHokkaido University Hospital · JPJapanese Red Cross Society, Japan · JPKawasaki Medical School · JPKeio University · JPKyushu University · JPNagano Red Cross Hospital · JPNagoya University · JPNational Hospital Organization · JPOkayama University Hospital · JPOsaka International Cancer Institute · JPShizuoka Cancer Center · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JPTokai University · JPTokyo Women's Medical University · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We retrospectively compared the outcomes of reduced-intensity conditioning (RIC) transplantation from matched related donors (MRD; n = 266), matched unrelated donors (MUD; n = 277), and umbilical cord blood (UCB; n = 513) for mature lymphoid malignancies. The 3-year overall survival rates for the MRD, MUD, and UCB groups were 54%, 59%, and 40%, respectively (P < 0.001). Multivariate analysis showed no differences in survival between the MRD group and the MUD or UCB group. However, survival was significantly affected by the conditioning regimen and graft-versus-host disease (GVHD) prophylaxis in the UCB group, but not in the MRD and MUD groups. Notably, multivariate analysis showed that the risk of overall mortality in the UCB recipients who received the optimal conditioning regimen and GVHD prophylaxis (n = 116) was lower than that in the MRD group (relative risk [RR], 0.69; P = 0.03) and tended to be lower than that in the MUD group (RR, 0.75; P = 0.09). Our results suggest that UCB transplantation performed with the optimal conditioning regimen and GVHD prophylaxis is highly effective. Moreover, UCB is readily available. Thus, UCB transplantation with the optimal conditioning regimen and GVHD prophylaxis is preferable to MUD transplantation when MRD are not available in the setting of RIC transplantation for mature lymphoid malignancies.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationNeoplasmsHumansRetrospective StudiesStem Cell TransplantationTransplantation ConditioningTransplantation, HomologousUnrelated Donors

Identifiers

PMID34815519
OpenAlexW3217376060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.